Recent News

• 04.14.2025 - ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
• 03.13.2025 - ProQR Announces Year End 2024 Operating and Financial Results
• 03.13.2025 - ProQR Announces Year End 2024 Operating and Financial Results
• 12.11.2024 - ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
• 12.11.2024 - ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
• 12.11.2024 - ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

Recent Filings

• 03.25.2025 - EFFECT Notice of Effectiveness
• 03.25.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.13.2025 - F-3 Registration statement by foreign private issuers
• 03.13.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.13.2025 - EX-99.1 EX-99.1
• 03.13.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.12.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 12.12.2024 - 6-K/A Report of foreign issuer [Rules 13a-16 and 15d-16]